Celon Pharma (CLN) Q1 2026 earnings summary

Executive summary

• Revenue increased by 25% year-over-year to PLN 61.9m, driven by both generic and innovative segments.

• Net profit reached PLN 162.6m, reversing a PLN 25.1m loss a year earlier, due to a one-time gain from fair value revaluation of Novohale shares.

• Operating loss (EBIT) narrowed to PLN 6.0m from PLN 18.8m, and EBITDA turned positive at PLN 5.2m versus a negative PLN 5.5m last year.

• Generic segment remains profitable and funds innovative R&D, which benefited from grants and service revenues.

Financial highlights

• Consolidated revenue: PLN 61.9m (up from PLN 49.3m year-over-year).

• Net profit: PLN 162.6m (vs. PLN -25.1m year-over-year), mainly due to a one-off gain from Novohale.

• Operating loss (EBIT): PLN -6.0m (improved from PLN -18.8m year-over-year).

• EBITDA: PLN 5.2m (vs. PLN -5.5m year-over-year).

• Net cash from operations: PLN -11.0m (vs. PLN -3.5m year-over-year).

• Total assets: PLN 670.7m (up from PLN 457.5m at year-end 2025).

Outlook and guidance

• Management expects continued growth in both generic and innovative segments, supported by new product launches and ongoing R&D partnerships.

• Key drivers include export growth of Salmex, commercialization of innovative drugs, and further grant funding.

• No formal financial guidance for 2026 was published.